A BILL directing the Virginia State Crime Commission to analyze kratom enforcement and regulation in the United States; report.
HB442 directs the Virginia State Crime Commission, working with the Board of Pharmacy, to study how kratom (Mitragyna speciosa) and 7-hydroxymitragynine (7-OH) are enforced and regulated across the United States. The study must examine federal status, whether states treat these substances through criminal laws or consumer protection laws, what penalties apply for possession or retail sales, and any other relevant issues the Commission identifies. The Commission must also develop recommendations for possible changes to Virginia law and submit an executive summary and report to the Governor and General Assembly by December 1, 2026.
The bill does not itself change Virginia’s criminal or regulatory laws governing kratom. Instead, it creates a formal legislative study and reporting requirement, with state agencies required to assist the Commission upon request. Its practical effect is to gather information that could support future policy decisions on whether Virginia should regulate, restrict, or otherwise address kratom and 7-OH.
HB442 would not immediately amend the Code of Virginia or create new penalties, licensing rules, or consumer protections. Its legal impact is limited to directing the Virginia State Crime Commission to conduct a statewide policy analysis and report findings and recommendations to the Governor and General Assembly. The bill could influence future legislation affecting kratom retailers, consumers, law enforcement, the Board of Pharmacy, and other agencies if the Commission recommends statutory changes.
Based on the bill’s posture and lack of recorded debate or votes, the measure appears to be a low-conflict study bill rather than a contested regulatory proposal. Its referral to and remaining in the House Rules Committee suggests it was treated as a preliminary information-gathering measure. With no committee transcript or voting history available, there is no evidence in the record provided of organized support or opposition, but the bill’s neutral fact-finding purpose typically indicates limited immediate controversy.
The main policy issue underlying HB442 is how Virginia should classify and regulate kratom and 7-OH: as substances warranting criminal enforcement, as consumer products subject to safety rules, or through some hybrid approach. Potential points of contention include whether kratom should be treated like an opioid-like substance, whether possession and retail sales should carry penalties, and whether regulation should be left to consumer protection authorities rather than criminal law enforcement. Stakeholders likely to differ include public health advocates, law enforcement, retailers, consumers, and proponents of herbal supplement access.